2023
A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
Chen Y, Lin X, Zou X, Qian Y, Liu Y, Wang R, Wang X, Yu X, Liu C, Cheng H. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. BMC Gastroenterology 2023, 23: 113. PMID: 37024802, PMCID: PMC10080823, DOI: 10.1186/s12876-023-02748-w.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsExpression of OX40Risk score modelImmune cellsIdentified OX40Immune checkpointsOverall survivalScoring systemRisk scoreClinical specimensExpression of immune checkpoint genesCD8+ T cellsImmune checkpoint gene expressionSomatic mutationsProtein expressionHigh-risk score groupImmunogenic cell deathCheckpoint gene expressionImmune checkpoint expressionImmune checkpoint genesImmune cell infiltrationNaive B cellsCox regression analysisAssociated with increased survival ratesRisk scoring system
2018
Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma
Liu C, Cheng H, Jin K, Guo M, Lu Y, Wang Z, Yang C, Long J, Ni Q, Yu X, Luo G. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Pancreas 2018, 47: 742-747. PMID: 29851752, DOI: 10.1097/mpa.0000000000001073.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerAmerican Joint Committee on Cancer stageTumor resectionPancreatic cancerEighth editionAmerican Joint Committee on Cancer eighth editionAmerican Joint Committee on Cancer seventh editionStage classificationLymph node involvementEnd Results registrySeventh editionPrognosis to patientsNode involvementTumor diameterPositive nodesInstitutional seriesPancreatic adenocarcinomaCancer stageStage distributionSurvival curvesPatientsSurvival analysisTumorStatistical differenceCancer
2016
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016, 16: 1057-1062. PMID: 27692554, DOI: 10.1016/j.pan.2016.09.013.Peer-Reviewed Original ResearchConceptsDetect pancreatic cancerCut-off valueSensitivity of CA19-9CA19-9Pancreatic cancerEffectiveness of CA19-9Secretor genotypeStaging of pancreatic cancerII pancreatic cancerDetection of stage INegative predictive valueCohort of subjectsCA19Carbohydrate antigenStage IPredictive valueSanger sequencingCancerSecretor statusSecretorEarly detectorGenotypic backgroundGroup
2015
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinoma
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survivalSrc Inhibition Is Still a Relevant Target in Pancreatic Cancer
George T, Trevino J, Liu C. Src Inhibition Is Still a Relevant Target in Pancreatic Cancer. The Oncologist 2014, 19: 211-211. PMID: 24457377, PMCID: PMC3926798, DOI: 10.1634/theoncologist.2013-0410.Peer-Reviewed Original Research
2012
Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis
Jeung J, Patel R, Vila L, Wakefield D, Liu C. Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis. Archives Of Pathology & Laboratory Medicine 2012, 136: 610-7. PMID: 22646266, PMCID: PMC3806979, DOI: 10.5858/arpa.2011-0371-oa.Peer-Reviewed Original ResearchConceptsHER2/neu expressionHER2/neu overexpressionGE tumorsBreast cancerNeu expressionNeu overexpressionIHC expressionHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Anti-HER2/neu antibodyGE junction tumorsGrowth factor receptor 2IHC interpretationIHC scoring systemHER2/neuFactor receptor 2Conventional light microscopyGastroesophageal adenocarcinomaOverall survivalClinicopathologic featuresIHC 3Resection specimensIHC 2Tumor gradeBreast carcinomaRepertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
Jenq R, Curran M, Goldberg G, Liu C, Allison J, van den Brink M. Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLOS ONE 2012, 7: e35222. PMID: 22493742, PMCID: PMC3320876, DOI: 10.1371/journal.pone.0035222.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAnimalsAntigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDEAD-box RNA HelicasesFemaleGraft vs Host DiseaseHumansImmunotherapy, AdoptiveLymphocyte CountMaleMiceMinor Histocompatibility AntigensNeoplasm TransplantationProstatic NeoplasmsSex FactorsWhole-Body IrradiationConceptsCD4 T cellsT cellsProstatic adenocarcinoma cellsAdoptive transferProstate cancerEffective anti-tumor immune responseCancer-reactive T cellsCD8 T cell responsesHigh-affinity T cellsPotential tumor rejection antigensTRAMP-C2 tumor cellsAnti-tumor immune responseAdenocarcinoma cellsExacerbation of graftPresence of CD25Female lymphocytesRegulatory T cellsAdoptive transfer modelReactive T cellsT cell responsesT cell repertoireMurine prostate cancerProstate cancer antigenAdult male hostsTumor rejection antigens
2010
Gastroduodenal Ulcerations As a Delayed Complication of Hepatic Metastasis Radioembolization
Nair J, Liu C, Caridi J, Zlotecki R, George T. Gastroduodenal Ulcerations As a Delayed Complication of Hepatic Metastasis Radioembolization. Journal Of Clinical Oncology 2010, 28: e735-e736. PMID: 20823407, DOI: 10.1200/jco.2010.29.5782.Peer-Reviewed Original Research
2009
Loss of Carbamoyl Phosphate Synthetase I in Small-Intestinal Adenocarcinoma
Cardona D, Zhang X, Liu C. Loss of Carbamoyl Phosphate Synthetase I in Small-Intestinal Adenocarcinoma. American Journal Of Clinical Pathology 2009, 132: 877-882. PMID: 19926579, DOI: 10.1309/ajcp74xgrfwtflju.Peer-Reviewed Original ResearchConceptsCases of duodenitisWestern blot analysisHep Par 1 antibodyHep Par 1 expressionHep Par 1Low-grade dysplasiaPAR-1 expressionBlot analysisExpression of CPS1CPS1 expressionIntestinal adenocarcinomaImmunohistochemical findingsInvasive adenocarcinomaInvasive tumorsMalignant tumorsAntigen expressionNormal mucosaControl groupAdenocarcinomaPAR-1AdenomasSmall intestine enterocytes